Bayer's MRI contrast agent gets FDA approval for use in cardiac disease [Reuters]
BAYER AG S/ADR (BAYRY)
NASDAQ:AMEX Investor Relations:
investor.bayer.com
Company Research
Source: Reuters
Bayer's MRI contrast agent gets FDA approval for use in cardiac disease - Reuters 1 Min Read (Reuters) - Bayer AG on Monday said U.S. regulators approved its contrast agent for use in magnetic resonance imaging (MRI) to assess patients with known or suspected coronary artery disease. The injection, Gadavist, is an approved agent for use in MRI of the central nervous system and breasts. Contrast agents are used to make MRI scans easier to see. Gadavist is the only contrast agent approved by the U.S. Food and Drug Administration for use in cardiac MR, an important diagnostic tool for patients with coronary artery disease (CAD), Bayer said. The approval was based on two multinational late-stage studies of nearly 1,000 adults with suspected or known CAD based on signs and symptoms. CAD develops when the major blood vessels that supply the heart with blood, oxygen and nutrients become damaged or diseased and affects about 16.5 million Americans, the company said. Reporting by Manojna Maddi
Show less
Read more
Impact Snapshot
Event Time:
BAYRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BAYRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BAYRY alerts
High impacting BAYER AG S/ADR news events
Weekly update
A roundup of the hottest topics
BAYRY
News
- Michael L. Baum, Esq. Renowned Advocate Added to Board of Gene Guard Detox, Inc. [Yahoo! Finance]Yahoo! Finance
- Indapta Therapeutics Secures $22.5 Million to Advance Clinical Trials of Innovative Cancer and Autoimmune Treatments [Yahoo! Finance]Yahoo! Finance
- Agrochemicals Market Poised for Significant Growth, Projected to Reach $282.2 Billion by 2028 [Yahoo! Finance]Yahoo! Finance
- Pet Supplements Market to Reach $4.68 Billion by 2031- Exclusive Report by Meticulous Research® [Yahoo! Finance]Yahoo! Finance
- Watermelon Seeds Market Analysis Report 2025-2030, Featuring Bayer CropScience, Vilmorin & Cie, Syngenta, Origene Seeds, GoldSupplier, Tokita Seed Co., Emerald Seed Company & Hazera [Yahoo! Finance]Yahoo! Finance